Echocardiographic Abnormalities and Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus

Falcão, Creso Abreu; Alves, Izabel Cristina; Chahade, Wiliam Habib; Duarte, Ângela Luzia Branco Pinto; Lucena‐Silva, Norma

doi:10.1590/s0066-782x2002001200008

Cited by 25 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-cardiolipin antibodies 84,85 were associated with PAH in several series of patients with SLE, similar to the findings in some studies of CTEPH. 86,87 In the study of Asherson et al, 85 68% of the patients with SLE and PAH had antiphospholipid antibodies.…”

Section: Evaluating Connective Tissue Disease or Other Risk Factors Fsupporting

confidence: 87%

Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension

McGoon

Gutterman

Steen

et al. 2004

Chest

796

622

View full text Add to dashboard Cite

Section: Evaluating Connective Tissue Disease or Other Risk Factors Fsupporting

confidence: 87%

Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension

McGoon

Gutterman

Steen

et al. 2004

Chest

796

622

View full text Add to dashboard Cite

“…Previous studies have shown the prevalence of heart valve disease in SLE has ranged from 12 to 73% [16][17][18][19][20][21]. Vivero [22], while the prevalence of this report was higher than that of our study (15.6%).…”

Section: Discussioncontrasting

confidence: 84%

Cardiac manifestations of Han Chinese patients with systemic lupus erythematosus: a retrospective study

et al. 2018

View full text Add to dashboard Cite

Objective To investigate cardiac manifestations and the risk factors in Han Chinese patients with systemic lupus erythematosus (SLE). Methods Seven hundred fifty SLE patients who were hospitalized at our department were recruited in the present study. The patients were divided into two groups-those with or without cardiac manifestations. Cardiac manifestations in those SLE patients, such as pericarditis, myocarditis, heart valve disease, arrhythmia, were analyzed. The risk and protective factors of cardiac diseases in patients with SLE, as well as the predictors of mortality, were assessed, respectively. Results In all 750 SLE patients, there were 339 (45.20%) patients suffered from one or more cardiac manifestations, involving pericarditis in 9.5%, myocarditis in 5.7%, heart valve disease in 15.6%, arrhythmia in 16.67%, and cardiovascular diseases (CVD) in 14%. 15.7% of SLE patients were accompanied with pulmonary arterial hypertension (PAH), of which 13.7% were mild, 1.2% were moderate, and 0.8% were severe. No significant differences were found between the two groups in age, disease duration, gender, antibody, and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). The incidence of pericarditis, heart valve disease, arrhythmia, and PAH was positively correlated with age. The incidence of arrhythmia, CVD, and PAH was correlated with SLEDAI. PAH and myocarditis were the risk factors of mortality in SLE patients with disease duration ≤ 10 years (P = 0.034 and 0.001, respectively). Conclusion Cardiac involvement is common in Han Chinese SLE patients and associated with age and disease activity. PAH and myocarditis are the risk factors of mortality in SLE.

show abstract

“…[32][33][34] Other studies have attributed LV hypertrophy in SLE to the additional presence of hypertension. [35][36][37][38] Our study documents that hypertension is not the primary cause of LV hypertrophy in SLE on the basis of comparable prevalences of hypertension in the patient and reference groups and on subgroup analyses in normotensive and hypertensive subjects demonstrating that the presence of both SLE and hypertension leads to increases in LV mass beyond the presence of hypertension alone. These findings are even more striking in that the diagnosis of hypertension may be less robust in SLE patients (ie, blood pressure may be primarily or exclusively elevated during flares, and antihypertensive medications were not discontinued for study purposes in SLE patients, whereas they were discontinued for weeks to months in our hypertensive referent subjects).…”

Section: Discussionmentioning

confidence: 60%

Systemic Lupus Erythematosus Predicts Increased Left Ventricular Mass

et al. 2007

View full text Add to dashboard Cite

Background-Systemic lupus erythematosus (SLE) is associated with premature atherosclerosis and vascular stiffening.Whether SLE alters left ventricular (LV) structure and function in the absence of valvular and clinical coronary artery disease is unknown. Methods and Results-SLE patients without clinical or echocardiographic evidence of valvular or coronary disease were age and gender matched to a reference group (nϭ173 in both groups). Subjects underwent echocardiography to quantify LV structure and function and carotid ultrasonography to detect atherosclerosis. Disease characteristics and radial applanation tonometry to measure arterial stiffness were evaluated in SLE patients. The 2 groups were similar in subjects' body size, hypertension and diabetes status, smoking status, and cholesterol levels. LV mass (38.3 versus 32.8 g/m 2.7 ), ejection fraction (71% versus 67%), and prevalence of LV hypertrophy (17.9% versus 6.4%) were higher in SLE patients than in referent subjects (all PϽ0.001). The combination of SLE and hypertension further increased LV mass. In multivariable analysis, LV mass was associated with SLE (PϽ0.001) in addition to body mass index, diabetes mellitus, and hypertension. Among SLE patients, LV mass was associated with arterial stiffness (PϽ0.001). Carotid atherosclerosis, SLE duration, damage index, serum creatinine, and homocysteine were significantly related to LV mass in univariate but not multivariable analyses. Conclusions-SLE predicts increased LV mass, possibly because of inflammation-related arterial stiffening. Excess LV hypertrophy may contribute to the increased cardiac morbidity and mortality observed in SLE patients. (Circulation.

show abstract

Echocardiographic Abnormalities and Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus

Abstract: Objective -Lupus anticoagulant and anticardiolipin antibodies (aCL)

Cited by 25 publications

References 43 publications

Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension

Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension

Cardiac manifestations of Han Chinese patients with systemic lupus erythematosus: a retrospective study

Systemic Lupus Erythematosus Predicts Increased Left Ventricular Mass

Contact Info

Product

Resources

About